Marno C. M. Rijk, MD; Ruud A. van Hogezand, MD, PhD; Henk J. J. van Lier, MSc; Jan H. M. van Tongeren, MD, PhD
Objective: To determine whether sulphasalazine plus prednisone is more effective than sulphasalazine alone in treating active Crohn disease.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: Multicenter trial in one university hospital and nine general hospitals.
Patients: Patients with active Crohn disease and a Van Hees Activity Index of 140 or more. Of 71 patients who were randomly assigned, 60 completed treatment and were analyzed.
Interventions: For 16 weeks, 30 patients received sulphasalazine, 6 g/d (or 4 g/d if adverse effects occurred) and prednisone, 30 mg/d initially. Prednisone therapy was tapered in increments of 5 mg/2 wk to 10 mg/d after 8 weeks. Thirty other patients received sulphasalazine and a placebo.
Measurements and Main Results: In the first 6 weeks of treatment, the Van Hees Activity Index decreased to a median of 70% (interquartile range, 57% to 81%) of the initial value in patients treated with sulphasalazine and prednisone and to a median of 87% (interquartile range, 70% to 94%) in patients treated with sulphasalazine alone (P = 0.001). In the last 4 weeks of treatment, the corresponding figures were 63% (interquartile range, 40% to 75%) and 70% (interquartile range, 54% to 90%) (P = 0.10). The Crohn's Disease Activity Index decreased in the first 6 weeks to a median of 65% (interquartile range, 57% to 86%) in patients receiving sulphasalazine and prednisone and to a median of 75% (interquartile range, 58% to 101%) in patients receiving sulphasalazine alone (P = 0.13). In the last 4 weeks of treatment, the corresponding figures were 65% (interquartile range, 42% to 90%) and 76% (interquartile range, 49% to 110%) (P = 0.19).
Conclusions: The use of prednisone in addition to sulphasalazine in patients with active Crohn disease results in a significantly faster initial improvement, but not in a significantly better result after 16 weeks of treatment, when disease activity is measured by the Van Hees Activity Index.
Learn more about subscription options.
Register Now for a free account.
Rijk MCM, van Hogezand RA, van Lier HJJ, van Tongeren JHM. Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn Disease: A Double-Blind, Randomized, Multicenter Trial. Ann Intern Med. 1991;114:445–450. doi: 10.7326/0003-4819-114-6-445
Download citation file:
Published: Ann Intern Med. 1991;114(6):445-450.
Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only